Cargando…
Atg5(flox)-Derived Autophagy-Deficient Model of Pompe Disease: Does It Tell the Whole Story?
Autores principales: | Lim, Jeong-A, Zare, Hossein, Puertollano, Rosa, Raben, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640697/ https://www.ncbi.nlm.nih.gov/pubmed/29057281 http://dx.doi.org/10.1016/j.omtm.2017.08.002 |
Ejemplares similares
-
Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease
por: Meena, Naresh Kumar, et al.
Publicado: (2020) -
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
por: Spampanato, Carmine, et al.
Publicado: (2013) -
Modulation of mTOR signaling as a strategy for the treatment of Pompe disease
por: Lim, Jeong‐A, et al.
Publicado: (2017) -
AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice
por: Meena, Naresh K., et al.
Publicado: (2023) -
Impaired autophagy: The collateral damage of lysosomal storage disorders
por: Myerowitz, Rachel, et al.
Publicado: (2020)